Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis

Journal of Neuroimmunology

Volumn 180, Issue 1-2, 2006, Pages 147-158

  Julià, Eva ^a   Montalban, Xavier ^a   Al zayat, Hammad ^a   Issazadeh Navikas, Shohreh ^b   Goertsches, Robert ^a   Martin, Roland ^a   Comabella, Manuel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Apoptosis; Multiple sclerosis; T cells

Indexed keywords

BETA1A INTERFERON; CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; FAS ANTIGEN; FAS LIGAND; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD95; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; APOPTOSIS; AUTOIMMUNITY; BCL-2-ASSOCIATED X PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CHEMOTAXIS, LEUKOCYTE; DOWN-REGULATION; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CCR5; TNF RECEPTOR-ASSOCIATED DEATH DOMAIN PROTEIN;

EID: 33750618350     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.07.001     Document Type: Article

References (33)

1. Balachandran S., Roberts P.C., Kipperman T., Bhalla K.N., Compans R.W., Archer D.R., and Barber G.N. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J. Virol. 74 (2000) 1513-1523
2. Balashov K.E., Rottman J.B., Weiner H.L., and Hancock W.W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 6873-6878
3. Comi C., Leone M., Bonissoni S., DeFanco S., Bottarel F., Mezzatesta C., Chiocchetti A., Perla F., Monaco F., and Dianzani U. Defective T cell Fas function in patients with multiple sclerosis. Neurology 55 (2000) 921-927
4. Esplugues E., Sancho D., Vega-Ramos J., Martinez C., Syrbe U., Hammann A., Engel P., Sanchez-Madrid F., and Lauzurica P. Enhanced antitumor immunity in mice deficient in CD69. J. Exp. Med. 197 (2003) 1093-1106
5. Giuliani F., Goodyer C.G., Antel J.P., and Yong V.W. Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol. 171 (2003) 368-379
6. Gniadek P., Aktas O., Wandinger K.P., Bellmann-Strobl J., Wengert O., Weber A., von Wussow P., Obert H.J., and Zipp F. Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients. J. Neuroimmunol. 137 (2003) 187-196
7. Gomes A.C., Jonsson G., Mjornheim S., Olsson T., Hillert J., and Grandien A. Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand in peripheral blood mononuclear cells in relapsing-remitting multiple sclerosis. J. Neuroimmunol. 135 (2003) 126-134
8. Ichikawa H., Ota K., and Iwata M. Increased Fas antigen on T cells in multiple sclerosis. J. Neuroimmunol. 71 (1996) 125-129
9. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Boudette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer III F.E., Priore R.L., Pullicino P.M., Scherokman B.J., Whitham R.H., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39 (1996) 285-294
10. Kivisakk P., Cotleur A.C., Lee J.C., Rudick R.A., and Ransohoff R.M. Interferon-beta 1a does not reduce expression of CCR5 and CXCR3 on circulating T cells. J. Neuroimmunol. 141 (2003) 150-154
11. Lenardo M., Chan K.M., Hornung F., McFarland H., Siegel R., Wang J., and Zheng L. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17 (1999) 221-253
12. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46 (1996) 907-911
13. Macchi B., Matteucci C., Nocentini U., Caltagirone C., and Mastino A. Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis. NeuroReport 10 (1999) 399-402
14. Moser B., and Loetscher P. Lymphocyte traffic control by chemokines. Nat. Immunol. 2 (2001) 123-128
15. Najafiafn N., Chitnis T., Salama A.D., Zhu B., Benou C., Yuan X., Clarkson M.R., Sayegh M.H., and Khoury S.J. Regulatory functions of CD8+ CD28- T cells in an autoimmune disease model. J. Clin. Invest. 112 (2003) 1037-1048
16. Pender M.P. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 351 (1998) 978-981
17. Rep M.H.G., Schrijver H.M., van Lopik T., Hintzen R.Q., Roos M.T., Ader H.J., Polman C.H., and van Lier R.A. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-producing T cells in MS patients. J. Neuroimmunol. 96 (1999) 92-100
18. Sancho D., Gomez M., and Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 26 (2005) 136-140
19. Segal B.M., and Cross A.H. Fas(t) track to apoptosis in MS-TNF receptors may suppress or potentiate CNS demyelination. Neurology 55 (2000) 906-907
20. Sharief M.K. Impaired Fas-independent apoptosis of T lymphocytes in patients with multiple sclerosis. J. Neuroimmunol. 109 (2000) 236-243
21. Simpson J.E., Newcombe J., Cuzner M.L., and Woodroofe M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 84 (1998) 238-249
22. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., Qin S., Rottman J., Sellebjerg F., Strieter R.M., Frederiksen J.L., and Ransohoff R.M. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103 (1999) 807-815
23. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
24. Teleshova N., Pashenkov M., Huang Y.M., Soderstrom M., Kivisakk P., Kostulas V., Haglund M., and Link H. Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid. J. Neurol. 249 (2002) 723-729
25. Van Parijs L., and Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280 (1998) 243-248
26. Wang R., Rogers A.M., Ratliff T.L., and Russell J.H. CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors. J. Immunol. 157 (1996) 2961-2968
27. Weinstock-Guttman B., Badgett D., Patrick K., Hartrich L., Santos R., Hall D., Baier M., Feichter J., and Ramanathan M. Genomic effects of IFN-beta in multiple sclerosis patients. J. Immunol. 171 (2003) 2694-2702
28. Zang Y.C., Kozovska M.M., Hong J., Li S., Mann S., Killian J.M., Rivera V.M., and Zhang J.Z. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur. J. Immunol. 29 (1999) 1692-1700
29. Zang Y.C., Li S., Rivera V.M., and Hong J. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J. Immunol. 172 (2004) 5120-5127
30. Zipp F. Apoptosis in multiple sclerosis. Cell Tissue Res. 301 (2000) 163-171
31. Zipp F., Otzelberger K., Dichgans J., Martin R., and Weller M. Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis. J. Neuroimmunol. 86 (1998) 151-154
32. Zipp F., Beyer M., Gelderblom H., Wernet D., Zschenderlein R., and Weller M. No induction of apoptosis by IFN-beta in human antigen-specific T cells. Neurology 54 (2000) 485-487
33. Zipp F., Martin R., Lichtenfels R., Roth W., Dichgans J., Krammer P.H., and Weller M. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. J. Immunol. 159 (1997) 2108-2115